Journal article

Prevention of infant eczema by neonatal bacille Calmette-Guerin vaccination: The MIS BAIR randomized controlled trial

Laure F Pittet, Nicole L Messina, Kaya Gardiner, Bridget Freyne, Veronica Abruzzo, Kate L Francis, Clare Morrison, Christel Zufferey, Peter Vuillermin, Katrina J Allen, Anne-Louise Ponsonby, Roy Robins-Browne, Frank Shann, Katie L Flanagan, Rod Phillips, Susan Donath, Dan Casalaz, Nigel Curtis

ALLERGY | WILEY | Published : 2021


BACKGROUND: Bacille Calmette-Guérin (BCG) vaccine could play a role in counteracting the rising prevalence of atopic diseases, through its beneficial off-target effects. We aimed to determine whether neonatal BCG vaccination reduces the incidence of eczema in infants. METHODS: Randomized controlled trial with 1272 infants allocated to receive BCG-Denmark or no BCG at birth. The primary outcome was the 12-month incidence of eczema based on 3-monthly questionnaires. Eczema was also assessed at a 12-month clinic visit. NCT01906853. RESULTS: The 12-month eczema incidence was 32.2% in the BCG group compared with 36.6% in the control group (adjusted risk difference (aRD) -4.3%, ..

View full abstract


Funding Acknowledgements

National Health and Medical Research Council of Australia; The University of Melbourne, The Royal Children's Hospital Foundation and the Murdoch Children's Research Institute; Swiss National Science Foundation; Mercy Health; The Myers Foundation; The European Society of Pediatric Infectious Diseases; The Nossal Institute for Global Health; The Aranday Foundation